Biogen Pilot on Using Vocal Biomarkers to Identify Potential Trial Participants: From the DPHARM 2024 Archives
Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to identify potential patients and reduce the burden of pre-screening.
In this podcast from the DPHARM 2024 archives, Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition, and to reduce the burden of pre-screening.
For more information, go to DPHARMconference.com.
Related Podcasts
View All
Pfizer on Advancing Data Analysis Capabilities through A New EDC/CDMS Platform
How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost
Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?

